International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Trial Profile

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Imatinib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Dexrazoxane; Doxorubicin; Etoposide; Filgrastim; Folinic acid; Folinic acid; Hydrocortisone; Ifosfamide; Mercaptopurine; Mesna; Methotrexate; Methylprednisolone; Pegaspargase; Prednisolone; Tioguanine; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Sep 2017 Planned End Date changed from 1 Jul 2027 to 1 Jun 2026.
    • 06 Sep 2017 Planned primary completion date changed from 1 Dec 2025 to 1 Jun 2026.
    • 30 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top